araag2/HINT huggingface dataset:
Clinical trial NCT00215748 (phase 2, status: terminated)
Conditions: breast cancer, lung cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: dexamethasone
SMILES: C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  age ≥ 65 years;

          -  breast or lung cancer patients to receive docetaxel therapy as per protocol;

          -  corticosteroid administration, other than what is prescribed in this protocol, is not
             permitted during study participation, except topical administration and for adverse
             events;

          -  performance status ECOG 0-2;

          -  peripheral neuropathy ≤ 1;

          -  adequate kidney and liver functions

          -  signed study-specific informed consent

        Exclusion Criteria:

          -  Patients who have received an investigational drug within 4 weeks of registration;

          -  Prior or concurrent malignancies (other than surgically treated carcinoma in situ;

          -  Serious medical or psychiatric illness which would prevent informed consent;

          -  Life expectancy < 3 months;

          -  Active uncontrolled bacterial, viral, or fungal infection until these conditions are
             corrected or controlled.
Clinical trial NCT00616629 (phase 2, status: completed)
Conditions: atrial flutter
ICD codes: I48.3, I48.4, I48.92
Drugs: azd1305
SMILES: CC(C)(C)OC(=O)NCCN1C[C@H]2CN(CCOC3=CC=C(C=C3F)C#N)C[C@@H](C1)O2
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with atrial flutter (with a ventricular rate of <100 beats/minute at
             enrolment), scheduled for curative catheter ablation

          -  Sinus rhythm at randomisation

        Exclusion Criteria:

          -  QTc (Fridericia, QTcF ) >450 ms measured in sinus rhythm at randomisation,

          -  Serum potassium below 3.8 or above 5.0 mmol/L or plasma potassium below 3.6 or above
             5.0 mmol/L

          -  QRS duration >120 ms at randomisation
Clinical trial NCT01037907 (phase 2, status: terminated)
Conditions: relapsing remitting multiple sclerosis
ICD codes: M94.1, A68.9, A68.0, A68.1, M35.6
Drugs: pleneva tm bgc20-0134, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    lack of efficacy
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of relapsing MS according to the revised 2005 McDonald criteria

          -  Has shown disease activity defined by 1 or more MS attack within the last year which
             has been documented in prior medical notes and or the presence of active lesions on
             historical scans being either (based on radiology report or investigator review of
             MRI):

          -  Gd-enhancing on any scan obtained in the last year, or

          -  new T2 lesions between two scans both obtained within the last year

          -  A minimum total of 9 T2 lesions reported on a recent MRI obtained within 1 month prior
             to the screening visit

          -  Baseline EDSS score 0 - 5.5

          -  Has refused to be treated with approved disease modifying therapies available for MS,
             for any reason and once the investigator has fully informed the patient about the
             related benefits and potential adverse events associated with such treatments. Also,
             patients for whom such treatments have proved to be intolerable

        Exclusion Criteria:

          -  Has experienced an MS relapse or received systemic corticosteroids or
             adrenocorticotropic hormone (ACTH) in the previous 1 month

          -  Has a secondary progressive (SPMS), progressive relapsing (PRMS), or primary
             progressive MS (PPMS).

          -  Has received any of the following agents to treat MS (approved or unapproved):

          -  Within the previous 3 months: interferon beta, glatiramer acetate, intravenous
             immunoglobulin or plasmapheresis

          -  Within the previous 12 months: natalizumab, daclizumab, cytapheresis, azathioprine,
             cladribine, cyclophosphamide, methotrexate, mitoxantrone, mycophenolate, pixantrone,
             sirolimus, tacrolimus, or other agents typically used to prevent transplant rejection
             or as cancer chemotherapy, excluding hormonal treatments

          -  Ever having received: stem cell or bone marrow transplant, total lymphoid irradiation,
             vaccine therapy for MS, or monoclonal antibodies whose effects may be longer than 1
             year (such as alemtuzumab or rituximab)

          -  Within the previous 3 months: any other agents given for the non-symptomatic treatment
             of MS which are not included above, including over-the-counter, herbal and nutritional
             supplements. However, if the agent is being taken primarily to treat another medical
             condition, then it is allowed as long as the dose is unchanged within the previous 3
             months and is unlikely to change before week 24.
Clinical trial NCT01253564 (phase 2, status: completed)
Conditions: malignant melanoma
ICD codes: C43.0, C43.31, C43.51, C43.9, C43.4, C43.52, C43.10
Drugs: ro5185426
SMILES: CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients, >/= 18 years of age

          -  Metastatic melanoma (Stage IV, American Joint Committee on Cancer) with BRAF mutation
             (cobas 4800 BRAF V600 Mutation Test)

          -  Brain metastases for which surgical resection is not a treatment option

          -  Patients must have failed at least one previous treatment for brain metastases

          -  Requiring corticosteroids for symptom control

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

        Exclusion Criteria:

          -  Increasing corticosteroid dose during the 7 days prior to study entry

          -  Previous malignancy within the past 2 years, except for basal or squamous cell
             carcinoma of the skin or carcinoma in-situ of the cervix

          -  Concurrent administration of any anticancer therapies other than those administered in
             the study

          -  Clinically significant cardiovascular disease or event within the 6 months prior to
             first dose of study drug
Clinical trial NCT01196871 (phase 2, status: completed)
Conditions: fabry disease
ICD codes: E75.21
Drugs: migalastat hcl
SMILES: OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Male diagnosed with Fabry disease and between 18 and 65 years of age, inclusive

          -  Body mass index between 18-35 kg per meter squared

          -  Had initiated treatment with agalsidase at least 1 month prior to screening, and had
             received at least 2 infusions before screening

          -  Had stable dose level, dosing regimen, and form of agalsidase for at least 1 month
             before screening

          -  Had an estimated creatinine clearance greater than or equal to 50 milliliters
             (mL)/minute at screening

          -  Agreed to use medically accepted methods of contraception during the study and for 30
             days after study completion

          -  Were willing and able to provide written informed consent

        Exclusion Criteria:

          -  Had a documented transient ischemic attack, ischemic stroke, unstable angina, or
             myocardial infarction within the 3 months before screening

          -  Had clinically significant unstable cardiac disease (for example, cardiac disease
             requiring active management, such as symptomatic arrhythmia, unstable angina, or New
             York Heart Association class III or IV congestive heart failure)

          -  History of allergy or sensitivity to study drug (including excipients) or other
             iminosugars (such as miglustat, miglitol)

          -  Required a concomitant medication prohibited by the protocol: Glyset® (miglitol), or
             Zavesca® (miglustat)

          -  Any investigational/experimental drug or device within 30 days of screening, except
             for use of investigational enzyme replacement therapy for Fabry disease

          -  Had any intercurrent illness or condition that might have precluded the participant
             from fulfilling the protocol requirements or suggested to the investigator that the
             potential participant might have had an unacceptable risk by participating in this
             study
Clinical trial NCT00595985 (phase 2, status: terminated)
Conditions: gastric cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: sorafenib
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Reason stopped: 
    low response rate, no evidence of pfs or os improved.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed advanced or metastatic adenocarcinoma of the stomach

          -  ECOG performance scale ≤ 2

          -  At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan)

          -  Adequate hepatic, renal, heart, and hematologic functions:

               -  platelets>80 × 109/L

               -  neutrophil>2.0 × 109/L

               -  serum creatinine ≤ 1.5mg/dl

               -  total bilirubin within upper limit of normal(ULN)

               -  serum transaminase ≤ 2.5 × the ULN

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Concurrent cancer

          -  History of other malignancies except cured basal cell carcinoma of skin and carcinoma
             in-situ of uterine cervix

          -  Neuropathy, brain, or leptomeningeal involvement

          -  Uncontrolled significant comorbid conditions and previous radiotherapy
Clinical trial NCT01009515 (phase 2, status: terminated)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: paclitaxel, carboplatin, temozolomide
SMILES: CN1N=NC2=C(N=CN2C1=O)C(N)=O
Reason stopped: 
    low accrual; target accrual not met
  
Eligibility criteria:

        Inclusion Criteria:

          -  All patients with biopsy proven advanced melanoma are eligible if there is measurable
             disease.

          -  Patients must have a life expectancy of at least 12 weeks.

          -  Prior surgery, immunotherapy, minimal chemotherapy (1 drug for less than 4 months), or
             radiotherapy for primary tumor is acceptable but must be completed at least 4 weeks
             from study entry, and patient should have completely recovered from such procedures.

          -  Patients must have a Zubrod performance status of 0-2.

          -  Patients must sign an informed consent.

          -  Patients should have adequate bone marrow function defined by an absolute peripheral
             granulocyte count of ≥ 1500 cells/mm3, hemoglobin > 8 g/dl, platelet count ≥ 100
             000/mm3.

          -  Patients should have a normal hepatic function with a total bilirubin < 1.5 the upper
             limit of normal (ULN) and serum glutamic oxaloacetic transaminase (SGOT) or serum
             glutamic-pyruvic transaminase (SGPT) < 2 times the upper limit of normal (ULN),and
             adequate renal function as defined by a serum creatinine ≤ 1.5 times the ULN.

          -  Men and women of childbearing potential must be willing to consent to using effective
             contraception while on treatment and at least for 3 months.

          -  Patients with brain metastases are eligible if they have been appropriately treated,
             are asymptomatic

        Exclusion Criteria:

          -  Pregnant women or nursing mothers are not eligible.

          -  Patients must not receive any other concurrent chemotherapy or radiation during this
             trial.

          -  Patients with severe medical problems that would interfere with the therapy are not
             eligible.
Clinical trial NCT00509769 (phase 2, status: completed)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: trastuzumab emtansine [kadcyla]
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent form.

          -  Human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer
             (MBC); tissue (slides or blocks) available for HER2 confirmation.

          -  History of progression on HER2-directed therapy for the treatment of HER2-positive
             breast cancer.

          -  At least 1, and no more than 3, chemotherapy regimens for MBC.

          -  Granulocyte count ≥ 1500/μL, platelet count ≥ 100,000/μL, and hemoglobin ≥ 9 g/dL.

          -  Serum bilirubin ≤ 1.5 mg/dL, aspartate aminotransferase (AST), alanine
             aminotransferase (ALT), and alkaline phosphatase ≤ 2.5x the upper limit of normal
             (ULN).

          -  Serum creatinine ≤ 1.5 mg/dL or creatinine clearance ≥ 60 mL/min.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

        Exclusion Criteria:

          -  Any chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or biological therapy
             for the treatment of breast cancer within 2 weeks of the first study treatment.

          -  Prior cumulative doxorubicin dose > 360 mg/m^2 or the equivalent.

          -  History of significant cardiac disease, unstable angina, congestive heart failure
             (CHF), myocardial infarction, or ventricular arrythmia requiring medication.
Clinical trial NCT00549770 (phase 2, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: lcz696, valsartan, ahu377, placebo
SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, [H][C@@](CC1=CC=C(C=C1)C1=CC=CC=C1)(C[C@@]([H])(C)C(=O)OCC)NC(=O)CCC(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or females from 18 up to and including 75 years

          -  Patients with mild-to-moderate uncomplicated essential hypertension, untreated or
             currently taking antihypertensive therapy (monotherapy or combination therapy of 2
             drugs; therapy with a fixed dose combination of two active substances represents 2
             drugs)

          -  Untreated patients must have had an office msDBP≥ 95 mmHg at the randomization visit
             (Visit 3) and the 2 preceding visits (Visits 1 and 2).

          -  Treated patients must have had an office msDBP≥ 90 mmHG after washout (Visit 2), and a
             msDBP> 95 mmHg at baseline (Visit 3);

        Exclusion Criteria:

          -  Severe hypertension (msSBP ≥180 mmHg and/or msDBP ≥110 mmHg)

          -  History of angioedema, drug-related or otherwise, as reported by the patient

          -  Type 1 or Type 2 diabetes mellitus (according to the ADA criteria)

          -  History or evidence of a secondary form of hypertension, such as renal parenchymal
             hypertension, renovascular hypertension, coarctation of the aorta, primary
             hyperaldosteronism, Cushing's disease, drug-induced hypertension, unilateral or
             bilateral renal artery stenosis, pheochromocytoma, polycystic kidney disease, etc.

          -  History of angina pectoris, myocardial infarction, coronary bypass surgery, ischemic
             heart disease, surgical or percutaneous arterial intervention of any kind (coronary,
             carotid or peripheral intervention), stroke, TIA (transient ischemic attack), carotid
             artery stenosis, aortic aneurysm or peripheral arterial disease
Clinical trial NCT00727207 (phase 2, status: terminated)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: everolimus
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Reason stopped: 
    lack of participations (8 of 25)
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of mantle cell lymphoma

          -  Stable disease after first- or second-line chemotherapy

          -  No uncontrolled cerebral or leptomeningeal disease

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-2

          -  Life expectancy ≥ 3 months

          -  Age ≥ 60 years or patients ≥ 40 and < 60 years who are not suitable for high-dose
             chemotherapy followed by autologous stem cell transplantation or allogeneic stem cell
             transplantation

          -  ANC ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin > 9 g/dL

          -  Serum creatinine ≤ 1.5 times upper limit of normal (ULN)

          -  SGPT and SGOT ≤ 3 times ULN

          -  Bilirubin ≤ 1.5 times ULN

          -  No other malignancies within the past 3 years except treated cervical carcinoma or
             basal cell cancer

          -  No other serious or non-controlled illnesses (e.g., diabetes mellitus, uncontrolled
             hypertension, serious infections, serious malnutrition, unstable angina pectoris, weak
             heart, myocardial infarction within the past 6 months, chronic liver illness, active
             ulceration in the gastrointestinal tract, psychiatric illness)

          -  No known HIV infection

          -  No gastrointestinal disturbances that could influence the absorption of everolimus and
             cause short-intestine syndrome (e.g., atrophic gastritis)

          -  No coagulation or bleeding diatheses

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  Patients must have complied with their previous drug prescription

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  See Patient Characteristics

          -  Recovered from all prior therapy

          -  At least 2 weeks since prior surgery, radiotherapy, or systemic antitumor therapy

          -  More than 4 weeks since prior experimental medication

          -  No chronic therapy with systemic steroids or other immunosuppressants except rituximab

          -  No prior organ transplantation

          -  No therapy with vitamin K antagonist, except low-dose coumarin

          -  No prior mTOR inhibitors
Clinical trial NCT01609478 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: indacaterol, placebo, mometasone furoate
SMILES: CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with persistent asthma, diagnosed according to GINA 2010 guideline and who
             additionally meet the following criteria:

          -  Patients who are receiving ICS treatment in a stable regimen for ≥ 4 weeks

          -  Patients with a pre-bronchodilator FEV1 value of ≥ 40% and ≤ 80% of predicted normal
             value

          -  Patients who demonstrate an increase of >= 12% and 200 mL in FEV1

          -  ACQ-5 score ≥ 1.5

        Exclusion Criteria:

          -  Patients who are current smokers or have a smoking history of greater than 10 pack
             years (defined as the number of packs of 20 cigarettes smoked per day multiplied by
             number of years the patient smoked).

          -  Patients with chronic lung disease, including COPD, pulmonary tuberculosis,
             bronchiectasis, sarcoidosis, interstitial lung disease and cystic fibrosis.

          -  Patients with any chronic conditions affecting the respiratory tract (e.g., chronic
             sinusitis) which in the opinion of the investigator may interfere with the study
             evaluation or optimal participation in the study.

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00698802 (phase 2, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ex1000, biphasic human insulin
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes for at least 12 months

          -  Current biphasic human insulin (BHI) for at least 3 months - as monotherapy or as the
             only insulin in combination with OADs

          -  Body Mass Index (BMI) less than or equal to 40.0 kg/m2

          -  HbA1c less than or equal to 9.5%

          -  FPG (SMPG) less than or equal to 12 mmol/L

        Exclusion Criteria:

          -  Treatment with more than 1IU/kg insulin daily

          -  Treatment with Glucagon-like peptide 1 mimetics or dipeptityl peptidase IV inhibitors

          -  Known hypoglycaemia unawareness or recurrent major hypoglycaemia, as judged by the
             Investigator

          -  Known or suspected allergy to trial products or related products

          -  Receipt of any investigational drug within one month prior to this trial

          -  Any other condition that the Investigator feels would interfere with trial
             participation or evaluation of results, e.g. shiftworkers
Clinical trial NCT00676403 (phase 2, status: completed)
Conditions: restless legs syndrome
ICD codes: G25.81
Drugs: placebo, pregabalin, pregabalin, pregabalin, pregabalin, pregabalin
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Moderate to severe idiopathic RLS

          -  symptoms occur predominantly in the evening

          -  symptoms interfere with sleep onset or maintenance

        Exclusion Criteria:

          -  Any secondary RLS

          -  require treatment for daytime RLS symptoms

          -  symptomatic neuropathies
Clinical trial NCT00357370 (phase 2/phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: dapagliflozin, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females, 18 to 75 years old, with type 2 diabetes with inadequate glycemic
             control

          -  Subjects receiving insulin and metformin and/or a thiazolidinedione

          -  Body Mass Index <=45.0 kg/m2

          -  Serum creatinine <1.5 mg/dL for men or <1.4 mg/dL for women

          -  No overt proteinuria (in subjects with a microalbumin/creatinine ratio ≥300 mg/g, the
             24-hour urinary excretion of total protein must be <3 g/24 hrs)

        Exclusion Criteria:

          -  History of type 1 diabetes

          -  AST and/or ALT >2.5 times the upper limit of normal

          -  Creatinine kinase ≥3 times the upper limit of normal

          -  Symptoms of severely uncontrolled diabetes

          -  History of hypoglycemic unawareness

          -  Currently unstable or serious cardiovascular, renal, hepatic, hematological,
             oncological, endocrine, psychiatric, or rheumatic diseases